Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,597,790
  • Shares Outstanding, K 62,292
  • Annual Sales, $ 27,120 K
  • Annual Income, $ -239,560 K
  • EBIT $ -180 M
  • EBITDA $ -167 M
  • 60-Month Beta 0.66
  • Price/Sales 88.14
  • Price/Cash Flow N/A
  • Price/Book 5.88

Options Overview Details

View History
  • Implied Volatility 267.45% (+5.98%)
  • Historical Volatility 82.59%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 267.45% on 02/09/26
  • IV Low 56.99% on 03/10/25
  • Expected Move (DTE 11) 4.18 (15.95%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 2,393
  • Volume Avg (30-Day) 6,861
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 171,054
  • Open Int (30-Day) 150,370
  • Expected Range 22.04 to 30.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.93
  • Number of Estimates 5
  • High Estimate -0.75
  • Low Estimate -1.05
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +38.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.15 +21.96%
on 01/14/26
28.48 -9.43%
on 02/03/26
+0.48 (+1.88%)
since 01/09/26
3-Month
19.29 +33.72%
on 12/15/25
31.43 -17.93%
on 11/11/25
-2.00 (-7.18%)
since 11/07/25
52-Week
7.76 +232.41%
on 04/09/25
71.50 -63.92%
on 10/28/25
+11.16 (+76.32%)
since 02/07/25

Most Recent Stories

More News
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme...

QURE : 25.86 (+0.82%)
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Feb. 1, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws...

QURE : 25.86 (+0.82%)
Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Jan. 17, 2026 /PRNewswire/ -- The law firm of  Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities...

QURE : 25.86 (+0.82%)
uniQure Announces Type A Meeting Scheduled with FDA

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

QURE : 25.86 (+0.82%)
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Jan. 8, 2026 /PRNewswire/ -- The law firm of  Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities...

QURE : 25.86 (+0.82%)
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP

The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) investors concerning the Company’s...

QURE : 25.86 (+0.82%)
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Dec. 29, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities...

QURE : 25.86 (+0.82%)
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Dec. 23, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws...

QURE : 25.86 (+0.82%)
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Dec. 16, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws...

QURE : 25.86 (+0.82%)
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Dec. 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws...

QURE : 25.86 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 30.22
2nd Resistance Point 29.12
1st Resistance Point 27.39
Last Price 25.86
1st Support Level 24.56
2nd Support Level 23.46
3rd Support Level 21.73

See More

52-Week High 71.50
Fibonacci 61.8% 47.15
Fibonacci 50% 39.63
Fibonacci 38.2% 32.11
Last Price 25.86
52-Week Low 7.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar